Microbot Medical Inc. has achieved commercial adoption of its LIBERTY Endovascular Robotic System by multiple accounts, including two that participated in the ACCESS-PVI pivotal clinical trial. This adoption follows the system's full market release and is supported by updated medical guidelines promoting reduced radiation exposure and better ergonomics. The company plans to boost its global presence at the upcoming GEST conference in New York and expand international sales with a new VP of Sales for EMEA. These steps aim to grow Microbot's footprint in endovascular robotic technology and improve interventional care worldwide.
Goodfirms has published its 2026 rankings of top technology service providers across six categories: mobile app, software, web development, digital marketing, SEO, and AI development. These rankings are based on over 1.2 million verified client revie...
Alvotech announced a $152 million public offering and concurrent private placement of ordinary shares priced at $3.75 each. The public offering includes 22.7 million shares, with an option for underwriters to buy an additional 3.4 million shares. The...
Alvotech announced pricing and allocation of a $152 million public share offering in the US and a concurrent private placement in Europe at $3.75 per share. The company expects total proceeds up to $165 million if underwriters exercise their full opt...
The Schall Law Firm has launched an investigation into Oxford Industries following the company's sharp revenue guidance cut on June 10, 2026, which caused a significant drop in its share price. The probe focuses on whether Oxford issued false or misl...
The global market for highway, street, and bridge construction is projected to grow from $1.28 trillion in 2025 to $2.18 trillion by 2035, at a compound annual growth rate of 4.8%. Growth is driven by government infrastructure spending, urbanization,...
